0.03Open0.03Pre Close0 Volume752 Open Interest2.50Strike Price0.00Turnover302.54%IV193.84%PremiumOct 18, 2024Expiry Date0.00Intrinsic Value100Multiplier20DDays to Expiry0.03Extrinsic Value100Contract SizeAmericanOptions Type0.1287Delta0.3418Gamma28.70Leverage Ratio-0.0031Theta0.0000Rho3.70Eff Leverage0.0004Vega
Microbot Medical Stock Discussion
Microbot Medical (MBOT.US)
Microbot Medical Announces the Successful Enrollment of 50% of the Patients in Its Pivotal Human Clinical Trial for the Liberty Endovascular Robotic Surgical System! Intends to submit to FDA for 510 (K) by EOY
Microbot Medical Announces the Successful Enrollment of 50% of the Patients in its Pivotal Human Clinical Trial for the LIBERTY Endovascular Robotic Surgical System
·1 min ago
Microbot Medical Signs Phase 2 Collaboration Agreement With Corewell Health to Advance Remote Telesurgery Using the Liberty® Endovascular Robotic System
Microbot Medical Completes the Enrollment of Clinical Sites in Its Pivotal Human Clinical Trial with the Addition of Memorial Sloan Kettering Cancer Center
Microbot Medical Inc. (Nasdaq: MBOT) has completed the enrollment of clinical sites for its pivotal human clinical trial of the LIBERTY® Endovascular Robotic Surgical System. Memorial Sloan Kettering Cancer Center in New York City joins Brigham and Women's Hospital in Boston and Baptist Hospital of Miami as the...
Benzinga-Second Site In Company's Pivotal Human Clinical Trial, Following Brigham & Women's Hospital, Supporting Future FDA Submission For Commercialization
No comment yet